David A. Siegel Cel Sci Corp Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$2.58 - $4.99 $251,292 - $486,026
-97,400 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$3.93 - $7.7 $255,843 - $501,270
65,100 Added 201.55%
97,400 $383,000
Q4 2021

Feb 14, 2022
SELL
$7.1 - $12.82 $226,490 - $408,958
-31,900 Reduced 49.69%
32,300 $229,000
Q3 2021

Nov 15, 2021
BUY
$7.64 - $12.49 $490,488 - $801,858
64,200 New
64,200 $706,000

Others Institutions Holding CVM

# of Institutions
71
Shares Held
6M
Call Options Held
27.1K
Put Options Held
150K
View Full List

About CEL SCI CORP

CVM Quotes by TradingView
  • Ticker CVM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,367,500
  • Market Cap $30.4M
  • Description
  • CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...
More about CVM
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email